ARWR Stock Price Today (October 2026) — Arrowhead Pharmaceuticals, Inc. Analysis & Key Metrics 2026-10-08
Arrowhead Pharmaceuticals, Inc. (ARWR) is trading at $60.74, down 1.20% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $107.23 (76.5% upside).
- Volatility is moderate (35.56% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (171.00% YoY) alongside competitive pressures in the Biotechnology space.
ARWR Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Arrowhead Pharmaceuticals, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $8.36B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+76.5% upside potential
Key Investor Questions About ARWR
What investors need to know before buying
Based on current market data, ARWR presents a oversold technical setup with caution warranted fundamentals.
- Technicals say: Oversold (RSI 22.09)
- Fundamentals say: Caution warranted (high leverage concerns)
ARWR's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ARWR investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.38B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ARWR stock traded between $34.61 and $95.49 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 35.56% annualized volatility and β=1.69, the stock exhibits high sensitivity to market moves—making ARWR suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near
Goldman sees biotech’s recent gains holding up despite macro pressures, supported by deal activity, clinical progress, and a more favorable regulatory backdrop.
Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds
Arrowhead Pharmaceuticals (ARWR) has drawn fresh attention after reporting interim Phase 1/2a data for ARO-DIMER-PA, its dual RNA interference candidate targeting atherosclerotic cardiovascular disease due to mixed hyperlipidemia. Arrowhead Pharmaceuticals has been volatile around the interim ARO-DIMER-PA update, with the share price down 19.76% over the past week and 25.65% over the past month. However, the 1 year total shareholder return of 116.62% and 3 year total shareholder return of...
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candidates during the Morgan Stanley Global Healthcare Conference. Early Dimer Data
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disord
Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’
Redemplo is already approved by the U.S. Food and Drug Administration (FDA) to lower very high triglycerides in the rare condition familial chylomicronemia syndrome.
Arrowhead Achieves Clinical Validation for New Drug Platform
Arrowhead Pharmaceuticals (NASDAQ:ARWR) on Tuesday shared interim topline clinical data from a Phase 1/2a trial. The trial is evaluating ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. Hyperlipidemia is defined by an excess of fats, or lipids—such as cholesterol and triglycerides—in the blood. Read Also: Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat Interim ARO-
ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?
ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Perry's liquidity event comes as the Arrowhead stock price surged.
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) presented detailed results from the randomized, double-blind, placebo-controlled Phase 3 SHASTA-3 and SHASTA-4 studies in 757 adults with severe hypertriglyceridemia. Four quarterly 25-mg doses of plozasiran produced median triglyceride reductions of 79% and 81% at Month 12, compared with approximately 27% for placebo in each study. A prespecified pooled analysis showed […]
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
Explore More Analysis for ARWR
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 23, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $60.74. The RSI (14-day) is at 22.1, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $107.23 implies 76.5% upside from current levels. Volatility is moderate at 35.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Arrowhead Pharmaceuticals, Inc. (ARWR): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 24.46. Price-to-Sales is 17.02. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 13 analysts covering ARWR, the consensus price target is $107.23. This represents a 76.5% upside from the current price of $60.74. The range spans from a low target of $74.00 to a high target of $126.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Arrowhead Pharmaceuticals, Inc. (ARWR) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Arrowhead Pharmaceuticals, Inc. (ARWR) investors include: 1. Moderate volatility (35.6% annualized)—price swings are notable. 2. Elevated debt levels (debt-to-equity of 2.96x) which could pressure margins in a rising rate environment. 3. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Arrowhead Pharmaceuticals, Inc.'s (ARWR) current debt and financial health profile: Total debt stands at $1.38B. The debt-to-equity ratio is 2.96x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 5.90, indicating strong short-term liquidity. The quick ratio is 5.71. The company holds $1.60B in cash and equivalents. Free cash flow is negative at -$48.63M, which could limit the company's ability to manage debt obligations.